Policy/Procedures related to gene/vector therapies

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

1 post / 0 new
Log in or register to post comments
Wed, 05/22/2024 - 15:36
#1
Katie Galbreath
Katie Galbreath's picture
Offline
Last seen: 3 months 3 weeks ago
Joined: 12/19/2019 - 12:58
Policy/Procedures related to gene/vector therapies

With the approval of several new gene/vector therapies and many more on the horizon, our institution is planning to develop policies and procedures to standardize our approach to storage, preparation, administration, decontamination, and disposal of gene/vector therapies.

Does your institution have standardized policies or procedures in place related to gene/vector therapies that you could share? For institutions utilizing Epic EMR, do you utilize any Epic functionality in the EMR to alert staff that a patient is receiving or has received gene/vector therapy?

Current agents we are giving: BCG, Zolgensma and Adstiladrin

Top